Biomarker for preclinical Alzheimer’s disease tagged posts

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s Disease and associate with neuronal injury markers

This secreted marker molecule, which can be measured from CSF taps, may provide clinicians with a rapidly detectable biomarker for the transition from preclinical Alzheimer’s disease to cognitive impairment and progression to full dementia. Such is the conclusion of a multi-center study on a large group of human patients, published online in EMBO Molecular Medicine.

Alzheimer’s disease, an increasing problem in today’s aging populations, is characterized by amyloid peptide plaques and tau protein aggregates in nerve cells...